EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hyperoside ameliorates NAFLD in rats via remodeling gut microbiota and reprogramming serum metabolic networks

Mingchun Huang, Ya Wang, Yanyan Li, Weiwei Zeng

Frontiers in Nutrition · 12.01.2026 · 12

DOI: 10.3389/fnut.2025.1741026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Nutrition, online erschienen am 12.01.2026. Verfasst von Mingchun Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study explores hyperoside’s therapeutic efficacy in non-alcoholic fatty liver disease (NAFLD) rats and its gut–liver axis mechanisms through integrated gut microbiota and metabolomics analyses.

Methods

The SD rats were divided into five groups (normal control, NAFLD model, low-dose hyperoside [0.6 mg/kg/day], high-dose hyperoside [1.5 mg/kg/day], and rosiglitazone positive control [5 mg/kg/day]) and treated for 12 weeks. Body weight, serum biochemistry (ALT, AST, TC, TG), liver histopathology (H&E, Sirius Red), hepatic mRNA expression ( Tlr4, Tnf-α, and α-SMA ), gut microbiota (16S rRNA sequencing), and serum metabolites (untargeted metabolomics) were assessed.

Results

Hyperoside dose-dependently reduced high-fat, high-sugar diet-induced body weight gain, liver index, and hepatic steatosis/fibrosis, lowered serum liver enzymes and lipid levels, and downregulated pro-inflammatory/fibrotic genes. It remodeled gut microbiota by enriching Lactobacillus and suppressing pathobionts (e.g., Streptococcus , Escherichia-Shigella ), reversed metabolic disturbances (e.g., 3-hydroxybutyric acid, diacylglycerols), and targeted glycine/serine/threonine and alpha-linolenic acid metabolism. Beneficial bacteria were negatively correlated with pro-inflammatory metabolites like lysophosphatidylcholine.

Conclusion

Hyperoside ameliorates NAFLD, which is associated with gut microbiota remodeling and modulation of host metabolic networks, supporting its potential as a multi-target therapeutic agent for NAFLD.

Schlagwörter

Stichwörter der Autor:innen

gut microbiotahyperosidelipid metabolismliver fibrosismetabolomicsnon-alcoholic fatty liver disease (NAFLD)

Autor:innen und Institutionen

  • Department of Pharmacy, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
  • Department of Pharmacy, The Sixth People's Hospital of Dongguan, Dongguan, China.
  • Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Zitieren

APA

Huang, M., Wang, Y., Li, Y., & Zeng, W. (2026). Hyperoside ameliorates NAFLD in rats via remodeling gut microbiota and reprogramming serum metabolic networks. Frontiers in Nutrition, 12. https://doi.org/10.3389/fnut.2025.1741026

Vancouver

Huang M, Wang Y, Li Y, Zeng W. Hyperoside ameliorates NAFLD in rats via remodeling gut microbiota and reprogramming serum metabolic networks. Frontiers in Nutrition. 2026;12. doi:10.3389/fnut.2025.1741026

BibTeX
@article{Huang2026,
  author = {Huang, Mingchun and Wang, Ya and Li, Yanyan and Zeng, Weiwei},
  title = {Hyperoside ameliorates NAFLD in rats via remodeling gut microbiota and reprogramming serum metabolic networks},
  journal = {Frontiers in Nutrition},
  year = {2026},
  volume = {12},
  doi = {10.3389/fnut.2025.1741026}
}
Kostenlos starten →